Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

For decades, synthetic biologists have been developing gene circuits that can be transferred into cells for applications such as reprogramming a stem cell into a neuron or generating a protein that ...

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on ...

Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025 Festival ...

Oct. 30, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...

REGENXBIO completes pivotal enrollment and initiates commercial production in Duchenne gene therapy programme: Rockville, Maryland Friday, October 31, 2025, 18:00 Hrs [IST] REGENX ...

Overview of Epigenetics MarketThe global Epigenetics Market is valued at USD 2.56 Billion in 2024 and is projected to reach a value of USD 9.11 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting ...

The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.

These upcoming presentations underscore the breadth and versatility of our ACT-UP1 platform,” said Xuehai Liang, Ph.D., Chief Executive Officer of Arnatar Therapeutics. “By demonstrating the ability ...